Organon & Co (OGN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Total Assets Chart for Organon & Co
Organon & Co (OGN) total assets for FY2025 were USD 12.9B, a -1.8% change from FY2024. Organon & Co's total assets grew from USD 10.5B in 2018 to USD 12.9B in 2025 (22.6% over 7 years). Total assets compound annual growth rate: 5-year CAGR of 4.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.61B
- Implied Share Price
- $13.75
- Enterprise Value
- $11.01B
- Revenue (TTM)
- $6.13B
- EBITDA
- $1.56B
- Profit Margin
- 3.41%
- Trailing P/E
- 17.63
- Forward P/E
- 5.09
- Price/Book (MRQ)
- 3.57
- Price/Sales (TTM)
- 0.59
- EV/EBITDA
- 8.39
- EV/Revenue
- 1.80
- Dividend Yield
- 0.58%
- Book Value
- $3.83
- Free Cash Flow (FY2025)
- $538.00M
- Free Cash Flow Yield
- 14.90%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.